elinzanetant

Small moleculeapproved

Approved

Oct 24, 2025

Clinical trial activity

17 trials · 2 clinical orgs · 1 marketing orgs

Phase 1
11
Phase 2
6
Phase 3
4
Phase 4
0

Earliest trial started Apr 9, 2021 (NCT04845841)

Timeline

2020s

  1. Jan 1, 2021

    Bayer — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2021

    Bayer — Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2023

    Bayer — Earliest Phase 2 Sponsor(trial)

  4. Oct 24, 2025

    Earliest FDA Approval

  5. Oct 24, 2025

    Bayer — Marketing Organization

Indications

Approved for

Mechanism of action

Approval history

  • approvedOct 24, 2025

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cc(F)ccc1-c1cc(N2C[C@H]3COCCN3C[C@H]2CO)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Mol. weight
668.65 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07077395Phase 2Jan 31, 2026Harvard University
NCT06219902Phase 1Jan 8, 2024Bayer
NCT06112756Phase 2Nov 8, 2023Bayer
NCT05587296Phase 3Oct 14, 2022Bayer
NCT05481528Phase 1Aug 19, 2022Bayer
NCT05471817Phase 1Aug 5, 2022Bayer
NCT05381142Phase 1May 23, 2022Bayer
NCT05351892Phase 1May 4, 2022Bayer
NCT05099159Phase 3Oct 29, 2021Bayer
NCT05071729Phase 1Oct 14, 2021Bayer
NCT05061563Phase 1Sep 30, 2021Bayer
NCT05028608Phase 1Sep 6, 2021Bayer
NCT05042362Phase 3Aug 27, 2021Bayer
NCT05030584Phase 3Aug 27, 2021Bayer
NCT04981431Phase 1Aug 11, 2021Bayer
NCT04889287Phase 1May 26, 2021Bayer
NCT04845841Phase 1Apr 9, 2021Bayer
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BayerFor profit161632021
Harvard UniversityAcademic/Hospital1112026
2 organizations
Page 1 / 1

Marketing (1)

OrganizationOrg typeRelationshipDate
BayerFor profitMKTGOct 24, 2025